{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:36:54Z","timestamp":1773970614817,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40744-022-00446-9","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T07:06:53Z","timestamp":1650870413000},"page":"1031-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry"],"prefix":"10.1007","volume":"9","author":[{"given":"Manuel Jos\u00e9","family":"Moreno-Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sanchez-Piedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rodr\u00edguez-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"P\u00e9rez-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"C\u00e1liz-Caliz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerusalem","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Mar\u00eda","family":"Blanco-Madrigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Moreno-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Linares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"S\u00e1nchez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sastr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Castrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"issue":"1","key":"446_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/clpt.2011.278","volume":"91","author":"DL Scott","year":"2012","unstructured":"Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91(1):30\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"446_CR2","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, G\u00f3mez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55(3):523\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"446_CR3","doi-asserted-by":"crossref","unstructured":"Ebina K, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis\u2014the ANSWER cohort study. PLoS ONE. 2018;13(3):e0194130.","DOI":"10.1371\/journal.pone.0194130"},{"issue":"4","key":"446_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.reuma.2017.08.001","volume":"15","author":"C Sanchez-Piedra","year":"2019","unstructured":"Sanchez-Piedra C, et al. Objectives and methodology of BIOBADASER phase iii. Reumatol Clin (Engl Ed). 2019;15(4):229\u201336.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"446_CR5","doi-asserted-by":"crossref","unstructured":"Baeten D, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","DOI":"10.1056\/NEJMoa1505066"},{"key":"446_CR6","doi-asserted-by":"crossref","unstructured":"Langley RG, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","DOI":"10.1056\/NEJMoa1314258"},{"issue":"9999","key":"446_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"6","key":"446_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"446_CR9","doi-asserted-by":"crossref","unstructured":"Torre Alonso JC, et al. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. Reumatol Cl\u00edn (Engl Ed). 2018;14(5):254\u201368.","DOI":"10.1016\/j.reumae.2017.08.002"},{"key":"446_CR10","doi-asserted-by":"crossref","unstructured":"van der Heijde D, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"446_CR11","doi-asserted-by":"crossref","unstructured":"Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","DOI":"10.1093\/med\/9780199642489.003.0114_update_003"},{"key":"446_CR12","doi-asserted-by":"crossref","unstructured":"Gratac\u00f3s J, et al. Recommendations by the Spanish Society of Rheumatology on the use of biological therapies in axial spondyloarthritis. Reumatol Clin (Engl Ed). 2018;14(6):320\u201333.","DOI":"10.1016\/j.reumae.2017.08.004"},{"key":"446_CR13","unstructured":"Spanish Society of Rheumatology. Clinical practice guideline for patients with axial spondyloarthritis and psoriatic arthritis [Internet]. Madrid: Spanish Society of Rheumatology; 2015."},{"key":"446_CR14","doi-asserted-by":"crossref","unstructured":"Papp KA, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","DOI":"10.1056\/NEJMoa1607017"},{"issue":"1","key":"446_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1\u00a0year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-69.e9.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"446_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acr2.11097","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18\u201325.","journal-title":"ACR Open Rheumatol"},{"issue":"10148","key":"446_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet. 2018;392(10148):650\u201361.","journal-title":"The Lancet"},{"key":"446_CR18","doi-asserted-by":"crossref","unstructured":"Reich K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","DOI":"10.1016\/j.jaad.2016.11.042"},{"issue":"5","key":"446_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17512433.2020.1759415","volume":"13","author":"F Bellinato","year":"2020","unstructured":"Bellinato F, Gisondi P, Girolomoni G. A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol. 2020;13(5):481\u201391.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"446_CR20","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum. 2013;65(5):1213\u201323.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"446_CR21","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","volume":"72","author":"KM Fagerli","year":"2013","unstructured":"Fagerli KM, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72(11):1840\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"446_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/ard.2007.082925","volume":"67","author":"LC Coates","year":"2008","unstructured":"Coates LC, et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis. 2008;67(5):717\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"446_CR23","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3899\/jrheum.100069","volume":"37","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010;37(9):1898\u2013906.","journal-title":"J Rheumatol"},{"issue":"1","key":"446_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3899\/jrheum.150744","volume":"43","author":"LE Kristensen","year":"2016","unstructured":"Kristensen LE, et al. Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from Southern Sweden. J Rheumatol. 2016;43(1):81\u20137.","journal-title":"J Rheumatol"},{"issue":"14","key":"446_CR25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"key":"446_CR26","doi-asserted-by":"crossref","unstructured":"Gentileschi S, et al. Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediat Inflamm. 2020;2020:1\u20135.","DOI":"10.1155\/2020\/6983272"},{"issue":"9","key":"446_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","volume":"79","author":"R Micheroli","year":"2020","unstructured":"Micheroli R, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2020;79(9):1203\u20139.","journal-title":"Ann Rheum Dis"},{"key":"446_CR28","doi-asserted-by":"publisher","unstructured":"Alonso S, et al. Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.679009.","DOI":"10.3389\/fmed.2021.679009"},{"key":"446_CR29","doi-asserted-by":"crossref","unstructured":"Michelsen B, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020;6(3):e001280.","DOI":"10.1136\/rmdopen-2020-001280"},{"key":"446_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24560","author":"B Michelsen","year":"2021","unstructured":"Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, M\u00f6ller B, Favalli EG, S\u00e1nchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, L\u00f6ve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, \u00d8rnbjerg LM, \u00d8stergaard M, Hetland ML. Real-world 6 and 12-month Drug Retention, Remission and Response Rates ofSecukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis Care Res (Hoboken). 2021. https:\/\/doi.org\/10.1002\/acr.24560.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"446_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745\u201357.","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"446_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"446_CR33","first-page":"372","volume":"31","author":"R Ariza-Ariza","year":"2004","unstructured":"Ariza-Ariza R, Hern\u00e1ndez-Cruz B, Navarro-Sarabia F. La versi\u00f3n espa\u00f1ola del BASDAI es fiable y se correlaciona con la actividad de la enfermedad. Rev Esp Reumatol. 2004;31(6):372\u20138.","journal-title":"Rev Esp Reumatol"},{"issue":"12","key":"446_CR34","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"8","key":"446_CR35","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, et al. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"446_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"446_CR37","doi-asserted-by":"crossref","unstructured":"Gentileschi S, et al. Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediators Inflamm. 2020;2020:6983272.","DOI":"10.1155\/2020\/6983272"},{"issue":"1","key":"446_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"10012","key":"446_CR39","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489\u201398.","journal-title":"Lancet"},{"issue":"11","key":"446_CR40","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","volume":"80","author":"A Molto","year":"2021","unstructured":"Molto A, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021;80(11):1436\u201344.","journal-title":"Ann Rheum Dis"},{"key":"446_CR41","doi-asserted-by":"crossref","unstructured":"Kivitz AJ, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447\u201362.","DOI":"10.1007\/s40744-018-0123-5"},{"issue":"1","key":"446_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.","journal-title":"Arthritis Res Ther"},{"key":"446_CR43","unstructured":"Deodhar ABR, Dokoupilova E, van de Sande M, Hall S, Wiksten A, Porter B, Richards H, Haemmerle S, Braun J. Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: results from a phase 3 double-blind, randomized, placebo-controlled study [abstract]. Arthritis Rheumatol. 2019;71(Suppl. 10)."},{"key":"446_CR44","doi-asserted-by":"crossref","unstructured":"Marzo-Ortega H, et al. 5-Year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2(6):e339\u201346.","DOI":"10.1016\/S2665-9913(20)30066-7"},{"issue":"4","key":"446_CR45","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","volume":"2","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol. 2020;2(4):e227\u201335.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"446_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39(5):327\u201346.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"446_CR47","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","volume":"65","author":"M Wakkee","year":"2011","unstructured":"Wakkee M, et al. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol. 2011;65(6):1135\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"446_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"updated-by":[{"DOI":"10.1007\/s40744-022-00479-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000}}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00446-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T13:00:16Z","timestamp":1664974816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00446-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00446-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}